DE602004027902D1 - Dna-vakzine gegen tumorwachstum und anwendungsverfahren dafür - Google Patents

Dna-vakzine gegen tumorwachstum und anwendungsverfahren dafür

Info

Publication number
DE602004027902D1
DE602004027902D1 DE602004027902T DE602004027902T DE602004027902D1 DE 602004027902 D1 DE602004027902 D1 DE 602004027902D1 DE 602004027902 T DE602004027902 T DE 602004027902T DE 602004027902 T DE602004027902 T DE 602004027902T DE 602004027902 D1 DE602004027902 D1 DE 602004027902D1
Authority
DE
Germany
Prior art keywords
human
protein
tumor growth
cancer
apoptosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602004027902T
Other languages
English (en)
Inventor
Rong Xiang
He Zhou
Ralph A Reisfeld
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scripps Research Institute
Original Assignee
Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Institute filed Critical Scripps Research Institute
Publication of DE602004027902D1 publication Critical patent/DE602004027902D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001136—Cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001148—Regulators of development
    • A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K6/00—Preparations for dentistry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
DE602004027902T 2003-03-24 2004-03-24 Dna-vakzine gegen tumorwachstum und anwendungsverfahren dafür Expired - Lifetime DE602004027902D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45700903P 2003-03-24 2003-03-24
PCT/US2004/008932 WO2004099389A2 (en) 2003-03-24 2004-03-24 Dna vaccines against tumor growth and methods of use thereof

Publications (1)

Publication Number Publication Date
DE602004027902D1 true DE602004027902D1 (de) 2010-08-12

Family

ID=33434911

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004027902T Expired - Lifetime DE602004027902D1 (de) 2003-03-24 2004-03-24 Dna-vakzine gegen tumorwachstum und anwendungsverfahren dafür

Country Status (18)

Country Link
US (2) US8716254B2 (de)
EP (1) EP1622648B1 (de)
JP (1) JP4616827B2 (de)
KR (1) KR101199789B1 (de)
CN (1) CN1791433B (de)
AT (1) ATE472339T1 (de)
AU (1) AU2004236636B2 (de)
BR (1) BRPI0408774A (de)
CA (1) CA2519953C (de)
DE (1) DE602004027902D1 (de)
DK (1) DK1622648T3 (de)
ES (1) ES2345200T3 (de)
MX (1) MXPA05010255A (de)
PL (1) PL1622648T3 (de)
PT (1) PT1622648E (de)
RU (1) RU2343195C2 (de)
WO (1) WO2004099389A2 (de)
ZA (1) ZA200508579B (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005294805B2 (en) 2004-05-28 2012-02-16 Oryxe A mixture for transdermal delivery of low and high molecular weight compounds
US20060276423A1 (en) * 2005-04-18 2006-12-07 Rachel Altura Survivin-directed RNA interference-compositions and methods
US20070104689A1 (en) * 2005-09-27 2007-05-10 Merck Patent Gmbh Compositions and methods for treating tumors presenting survivin antigens
KR100790377B1 (ko) * 2006-02-15 2008-01-02 고려대학교 산학협력단 인터페론감마를 발현하는 살모넬라 균주를 함유하는항바이러스용 조성물
WO2007149518A2 (en) * 2006-06-21 2007-12-27 The Scripps Research Institute Dna composition against tumor stromal antigen fap and methods of use thereof
EP2038417A2 (de) * 2006-07-06 2009-03-25 Merck Patent GmbH Zusammensetzungen und verfahren zur verstärkung der wirksamkeit von il-2-vermittelten immunreaktionen
FR2903605A1 (fr) * 2006-07-12 2008-01-18 Sanofi Pasteur Sa Methode d'immunisation contre les quatres serotypes de la dengue
FR2906724B1 (fr) * 2006-10-04 2009-03-20 Sanofi Pasteur Sa Methode d'immunisation contre les 4 serotypes de la dengue.
EP2102234A2 (de) * 2006-11-28 2009-09-23 GHC Research Development Corporation Polypeptide mit einer intrazytoplasmischen todesdomäne und einer nkg2d-ligandendomäne
FR2909286B1 (fr) * 2006-12-01 2012-06-08 Sanofi Pasteur Methode d'immunisation contre les 4 serotypes de la dengue
AU2009232774B2 (en) 2008-03-31 2014-05-29 Tella Inc. Partial peptide of Survivin presented on MHC class II molecule and use thereof
PT2411503T (pt) * 2009-03-27 2017-11-15 Eidgenössische Technische Hochschule Zürich Salmonella enterica que apresenta n-glicano de c. jejuni ou derivados do mesmo
BR112012002353A2 (pt) * 2009-08-17 2018-03-13 The Penn State Res Foudation uso de inibidores nkg2d para tratamento de doenças cardiovasculares e metabólicas, tal como diabetes do tipo 2
KR101815322B1 (ko) * 2010-01-12 2018-01-05 서울대학교산학협력단 항암 펩타이드 서열
KR102044948B1 (ko) * 2010-06-25 2019-11-14 백시바디 에이에스 동종이합체 단백질 구조물
CN102210862B (zh) * 2011-06-01 2013-06-12 中国人民解放军南京军区福州总医院 基于Livin的免疫刺激复合物及其制备方法和应用
IL298125A (en) * 2013-02-26 2023-01-01 Memorial Sloan Kettering Cancer Center Preparations and methods for immunotherapy
EP3607974A1 (de) * 2013-03-15 2020-02-12 The Trustees of The University of Pennsylvania Krebsimpfstoffe und verfahren zur behandlung unter verwendung davon
US20160058856A1 (en) * 2013-04-05 2016-03-03 Kyushu University, National University Corporation Anti-tumor dna vaccine
EP3016973A1 (de) * 2013-07-05 2016-05-11 INSERM - Institut National de la Santé et de la Recherche Médicale Neuartige alternative splice-transkripte für ketten-alpha der mhc-klasse i (mica) und verwendungen davon
WO2015139020A2 (en) * 2014-03-14 2015-09-17 Dana-Farber Cancer Institute, Inc. Vaccine compositions and methods for restoring nkg2d pathway function against cancers
MX2017002594A (es) * 2014-08-29 2017-05-19 Univ California Vacuna para sistemas de produccion ganadera.
US10414810B2 (en) 2015-05-07 2019-09-17 H. Lee Moffitt Cancer Center And Research Institute, Inc. Double mutant survivin vaccine
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
WO2017048807A1 (en) 2015-09-17 2017-03-23 Jrx Biotechnology, Inc. Approaches for improving skin hydration or moisturization
AU2016331052B2 (en) 2015-10-01 2023-08-03 Potenza Therapeutics, Inc. Anti-TIGIT antigen-binding proteins and methods of use thereof
US20190359940A1 (en) * 2017-02-07 2019-11-28 Agency For Science, Technology And Research Methods and kits for generating mimetic innate immune cells from pluripotent stem cells
JOP20190203A1 (ar) 2017-03-30 2019-09-03 Potenza Therapeutics Inc بروتينات رابطة لمولد ضد مضادة لـ tigit وطرق استخدامها
CN110448689A (zh) * 2019-08-06 2019-11-15 太仓美诺恒康生物技术有限公司 mRNA疫苗及其试剂盒、应用
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
AU2022208435A1 (en) 2021-01-18 2023-08-10 Conserv Bioscience Limited Coronavirus immunogenic compositions, methods and uses thereof
RU2770490C1 (ru) * 2021-07-14 2022-04-18 Федеральное государственное бюджетное научное учреждение "Федеральный исследовательский центр "Красноярский научный центр Сибирского отделения Российской академии наук" Рекомбинантная плазмидная ДНК pET19b-Surv-OL, обеспечивающая синтез гибридного белка сурвивин-обелин (Surv-OL) и гибридный белок, связываемый анти-сурвивин антителами и обладающий биолюминесцентной активностью
CN116077534A (zh) * 2023-01-31 2023-05-09 大连工业大学 一种凝结芽孢杆菌的应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3993223A (en) * 1974-07-25 1976-11-23 American Home Products Corporation Dispensing container
US5733760A (en) * 1994-08-05 1998-03-31 Virus Research Institute Salmonella vectors encoding truncated pag fusion protein, method of making, and uses thereof
US6190657B1 (en) * 1995-06-07 2001-02-20 Yale University Vectors for the diagnosis and treatment of solid tumors including melanoma
DE69739105D1 (de) * 1996-11-20 2008-12-24 Univ Yale Survivin, ein protein das zelluläre apoptosis hemmt, und dessen modulation
KR20080009171A (ko) * 1997-08-13 2008-01-24 더 유에이비 리서치 파운데이션 유전자 벡터의 국소 적용에 의한 백신접종
ES2251120T3 (es) * 1997-12-17 2006-04-16 Immunex Corporation Glicoproteinas de superficie celular asociadas a los linfomas b humanos-ulbp, adn y polipeptidos.
US20030215803A1 (en) * 2000-12-07 2003-11-20 Garcia Pablo Dominguez Human genes and gene expression products isolated from human prostate
AU4990999A (en) * 1998-07-14 2000-02-07 Jenner Biotherapies, Inc. Survivin, and peptides thereof, as an anti-cancer vaccine
US6472172B1 (en) * 1998-07-31 2002-10-29 Schering Aktiengesellschaft DNA encoding a novel human inhibitor-of-apoptosis protein
US6335194B1 (en) * 1998-09-29 2002-01-01 Isis Pharmaceuticals, Inc. Antisense modulation of survivin expression
US6838283B2 (en) * 1998-09-29 2005-01-04 Isis Pharmaceuticals Inc. Antisense modulation of survivin expression
IT1303683B1 (it) * 1998-10-30 2001-02-23 Menarini Ricerche Spa Composizione farmaceutiche ad azione antitumorale contenente dnacodificante per frammenti di una proteina antigenica.
US6413768B1 (en) * 1998-12-02 2002-07-02 University Of Maryland Expression plasmids
AU765160B2 (en) * 1998-12-18 2003-09-11 Symrise Gmbh & Co. Kg Encapsulated flavour and/or fragrance preparations
WO2002002622A2 (en) * 2000-06-29 2002-01-10 The Salk Institute For Biological Studies Crystal structure of survivin
EP1256354A1 (de) * 2001-05-11 2002-11-13 Schering Corporation Verfahren zur Behandlung von Krebs
WO2003031569A2 (en) * 2001-10-10 2003-04-17 Centocor, Inc. Nucleic acid vaccines using tumor antigen encoding nucleic acids with cytokine adjuvant encoding nucleic acid
US20080159957A1 (en) * 2002-10-01 2008-07-03 W Michael Kavanaugh Anti-Cancer and Anti-Infectious Disease Compositions and Methods for Using Same
JP2007527193A (ja) * 2002-12-10 2007-09-27 アンドキューブ ソシエタ パー アクシオン シンプリフィー ケモカインに対する核受容体としてのｔｈａｐタンパク質と、転写調節、細胞増殖、および細胞分化におけるその役割

Also Published As

Publication number Publication date
US8716254B2 (en) 2014-05-06
PL1622648T3 (pl) 2010-11-30
RU2005132578A (ru) 2006-05-10
JP4616827B2 (ja) 2011-01-19
KR101199789B1 (ko) 2012-11-09
RU2343195C2 (ru) 2009-01-10
ZA200508579B (en) 2007-04-25
MXPA05010255A (es) 2005-12-14
AU2004236636B2 (en) 2010-02-04
JP2006523217A (ja) 2006-10-12
US9655815B2 (en) 2017-05-23
KR20050121694A (ko) 2005-12-27
AU2004236636A1 (en) 2004-11-18
EP1622648A2 (de) 2006-02-08
EP1622648A4 (de) 2007-02-14
CN1791433A (zh) 2006-06-21
ES2345200T3 (es) 2010-09-17
CA2519953A1 (en) 2004-11-18
BRPI0408774A (pt) 2006-03-28
CN1791433B (zh) 2010-05-26
ATE472339T1 (de) 2010-07-15
US20140322249A1 (en) 2014-10-30
CA2519953C (en) 2016-01-05
DK1622648T3 (da) 2010-09-06
WO2004099389A3 (en) 2005-09-29
WO2004099389A2 (en) 2004-11-18
PT1622648E (pt) 2010-08-31
US20040192631A1 (en) 2004-09-30
EP1622648B1 (de) 2010-06-30

Similar Documents

Publication Publication Date Title
DE602004027902D1 (de) Dna-vakzine gegen tumorwachstum und anwendungsverfahren dafür
Pan et al. Recent development and clinical application of cancer vaccine: targeting neoantigens
Moore et al. Established T cell–inflamed tumors rejected after adaptive resistance was reversed by combination STING activation and PD-1 pathway blockade
Moschella et al. Combination strategies for enhancing the efficacy of immunotherapy in cancer patients
Kalinski et al. Dendritic cells in cancer immunotherapy: vaccines and combination immunotherapies
WO1998016238A3 (en) Cancer immunotherapy using tumor cells combined with mixed lymphocytes
Chiang et al. In vivo cancer vaccination: Which dendritic cells to target and how?
EA201000209A1 (ru) Новая иммунотерапия против нейрональных опухолей и опухолей головного мозга
WO2005081854A3 (en) Egf receptor epitope peptides and uses thereof
Petrulio et al. Development of the PANVAC™-VF vaccine for pancreatic cancer
Gillgrass et al. Stimulating natural killer cells to protect against cancer: recent developments
Morris et al. Vaccination with tumor cells expressing IL-15 and IL-15Rα inhibits murine breast and prostate cancer
NO20060813L (no) Syntetisk gen som koder for human epidermalvekstfaktor 2/NEU og andvendelser derav
CN106554416B (zh) 一种抗pd-l1人源化单克隆抗体联合干扰素基因刺激蛋白（sting）激动剂在抗肿瘤中的应用
AR068984A1 (es) Proceso para la obtencion de celulas presentadoras de antigenos activados, utiles en las terapias contra el cancer y enfermedades relacionadas del sistema inmunologico
Chen et al. Inhibition of mouse RM-1 prostate cancer and B16F10 melanoma by the fusion protein of HSP65 & STEAP1 186-193
Macedo et al. Intra-cheek immunization as a novel vaccination route for therapeutic vaccines of head and neck squamous cell carcinomas using plasmo virus-like particles
Nelson et al. Venezuelan equine encephalitis replicon immunization overcomes intrinsic tolerance and elicits effective anti-tumor immunity to the ‘self’tumor-associated antigen, neu in a rat mammary tumor model
Bedke et al. Immunotherapeutic strategies for the treatment of renal cell carcinoma: where are we now?
Tewari et al. Dendritic cell therapy in advanced gastric cancer: a promising new hope?
Kim et al. Modification of CEA with both CRT and TAT PTD induces potent anti-tumor immune responses in RNA-pulsed DC vaccination
Baba et al. Identification of a lung cancer antigen evading CTL attack due to loss of human leukocyte antigen (HLA) class I expression
Yang et al. Dendritic cells pulsed with GST–EGFR fusion protein: Effect in antitumor immunity against head and neck squamous cell carcinoma
CN115702927A (zh) 一种广谱性肿瘤疫苗增效的组合物
Elizondo et al. Analysis of the CD8+ IL-10+ T cell response elicited by vaccination with the oncogenic tumor-self protein D52